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Alzheimer’s disease (AD), the most common form of neuropsychiatric disorder, is characterized by neuronal degeneration and 
inexorably progressing dementia, especially in the elderly population. With a rapidly aging population in both developed and de-
veloping countries, AD has emerged as one of the largest growing problems worldwide. Current drugs improve the symptoms of 
AD, but do not have any profound intervention to delay its onset. Thus, understanding the molecular mechanisms underlying the 
genes tied to AD will be crucial to the development of therapeutic targets. This review will summarize the aetiology, pathology, 
and the evidence for the genetic components in AD, discuss the proposed amyloid cascade and the following tau hyperphosphor-
ylation hypothesises, oxidative stress mediated neuronal cell death, as well as the function of Retromer complex during the de-
veloping of AD. Our laboratory’s current research progress and the challenges that still remained will be also highlighted.  
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Alzheimer’s disease (AD), the most common form of demen-
tia, was first described by German neuropathologist Alois 
Alzheimer in 1906 [1]. In the autopsy report of a woman, 
who had died of a progressive cognitive disorder, Alois 
Alzheimer described two distinctive pathologies of the pa-
tient’s brain: neurofibrillary tangles, and senile plaques, both 
of which have become synonymous with Alzheimer’s dis-
ease [2].  
With a rapidly aging population, in most societies de-
mentia is becoming a major health burden. In 2009, 35.6 
million cases of AD were reported worldwide, and the 
number could be more than doubled by 2050 [3]. Conse-
quently, the total direct costs are estimated at $183 billion, 
and are expected to increase to $1.1 trillion by 2050 [4]. 
Because AD is degenerative and cannot be cured, most of 
the patients suffer an average of 4–8 years progression from 
the onset symptoms to death [5]. It places an exhausting and 
increasing burden on patients, caregivers and society.  
1  Aetiology and pathology 
It has been about a century since the description of the dis-
ease was developed by Alzheimer; we still do not fully un-
derstand what causes Alzheimer’s disease. Several lines of 
investigation generally indicate that there is unlikely to be a 
single clear “cause” of AD. It is more likely the result of a 
combination of inter-related factors, including aging, genetic 
factors, lifestyle factors, and environmental influences. Ag-
ing is the top risk factor for developing Alzheimer’s disease. 
Most patients with AD are diagnosed at age 65 or older, 
these individuals are said to have “late-onset” AD. Nearly 
10% of the population over the age of 65, and 50% of the 
population over the age of 85 have Alzheimer’s disease [6]. 
The probability of being diagnosed with AD nearly doubles 
every five years after age 65. However, people younger than 
age 65 can also develop the disease, which is defined as 
“early-onset” AD. Two kinds of genes have been demon-
strated as the genetic risk factors for AD. The first is 
thought to be a “risk gene”, ApoE 4 (the 4 allele of the 
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apolipoprotein E, ApoE4), the mutant of which has been 
shown increased the likelihood of developing late-onset AD 
[7]. However, why the mutated gene or different isoforms 
increase the risk of disease is still unclear. By contrast, 
around 0.1% of the cases are autosomal dominant familial 
forms, which usually have an early-onset (before age 65) [8]. 
The early-onset autosomal dominant familial AD (FAD) is 
usually attributed to mutations in one of three genes: amy-
loid precursor protein (APP), Presenilin 1 (PS1; also known 
as PSEN1) and PS2 (also known as PSEN2) [9]. APP is a 
single-pass transmembrane protein which is expressed highly 
in the synapses of neurons, and it has been found as an im-
portant regulator of neural plasticity [10] and synapse for-
mation [11]. APP processing generates the -amyloid (A) 
peptides, which are the main components of senile plaques 
in AD brains. Mutations in APP genes have been reported 
as the causal factors for early-onset FAD [12]. As the cata-
lytic components of -secretase complex, PS1 and PS2 are 
involved in A production by the proteolytic processing of 
APP [13]. PS mutations have been presumed to cause FAD 
by increasing the ratio of the more toxic A42 isoform to 
A40 [14]. At present, more than 100 different mutations in 
PS1 and PS2 have been associated with early-onset FAD 
[15]. These arguments support a role of A in the patho-
genesis of AD, and result in the formulation of the “Amy-
loid cascade hypothesis”, which will be further discussed in 
the next section.  
Although age and genetic mutations are out of our con-
trol, researchers have identified several lifestyle factors that 
can reduce a person’s risk of developing AD, such as 
avoiding tobacco, limiting alcohol consumption, and en-
gaging in intellectually stimulating activities [16]. Alumi-
num is one of the environmental factors that has been 
shown to be associated with both plaques and tangles in the 
AD brains [17], but no causal relationship has yet been 
proved. Formaldehyde, one of the most toxic organic com-
pounds, has been found to induce tau to form amyloid-like 
aggregates [18]. The authors further demonstrated that the 
urine formaldehyde concentrations of the elderly Alz-
heimer’s patients are significantly higher than that of nor-
mal elderly volunteers [19]. These data indicate that for-
maldehyde stress could be one of the mechanisms involved 
in the developing of AD.  
The neuropathologic changes of AD are characterized by 
loss of neurons and synapses in the neocortex and hippo-
campus regions [20]; both amyloid plaques and neurofibril-
lary tangles have been generally accepted as the hallmark 
lesions of AD. Senile plaques are mostly composed of insol-
uble A deposits and extracellular materials around neurons. 
Neurofibrillary tangles are formed by the intracellular mi-
crotubule-associated protein tau which has become hyper- 
phosphorylated [21]. Most studies agree that the classical 
pathological criteria for AD can account for 40%–70% of 
the cases [22], with additional pathologies such as Lewy 
body pathology [23] working together with AD pathology 
to account for an additional 20%–30% of dementia cases. 
Besides these hallmarks, over activation of the innate im-
mune response and inflammatory processes are also observed 
[24]. However, whether the abnormalities in these patho-
logical structures are the cause of the disease, or are only 
eventual reflections of the disease, remains elusive. So far, 
several lines of evidence have shown that there could be 
plausible cause-and-effect circuits that exist and exacerbate 
each other’s detrimental effects [25]. 
2  Amyloid cascade and tau hyperphosphoryla-
tion─Two main hypotheses  
A lot of pathological and aetiological hypotheses have been 
proposed, including genetics, calcium homeostasis dysfunc-
tion, oxidative stress, vesicle trafficking disruption, and 
inflammation with the resultant axon transport dysfunctions 
and cognitive decline. However, A cascade combining 
with tau hyperphosphorylation is still the major regarded 
pathogenetic mechanism [26].  
2.1  Amyloid cascade hypothesis 
According to the “amyloid cascade hypothesis”, A deposi-
tion is the crucial pathological trigger in the disease. The 
accumulated A subsequently leads to the formation of 
NFTs and eventually neuron loss. Early work has indicated 
that the A neurotoxicity requires the peptides to be assem-
bled into fibrillar, rather than soluble forms [27]. However, 
recent study demonstrates that soluble oligomeric A is the 
neurotoxic specie, but not the large amyloid deposit [28]. 
More studies demonstrate that A neurotoxicity depends on 
the interactions with copper ions, prion protein, and N-methyl- 
D-aspartate receptors [29,30]. Both necrotic and apoptotic 
processes have been found in AD brains as well as in cul-
tured neurons after exposed to A [31,32]. However, the 
precise mechanisms by which A peptide triggers cell death 
remain largely unknown. It has been reported that A dis-
turbs mitochondrial respiration and promotes the generation 
of reactive oxygen species (ROS) [33–35]. Furthermore, 
A-induced oxidative stress leads to neuronal cell death that 
can be inhibited by antioxidants [33,36,37]. Additionally, 
pathologic study has suggested that nitric oxide (NO) syn-
thases (NOSs) also appeared to participate in the pathogen-
esis of AD [38], and PS1 mutation-induced neurotoxicity is 
inhibited by NOS inhibitors [39]. These findings suggest 
that NO and ROS may be important mediators of A-in-       
duced neuronal cell death. However, how many down-
stream targets of ROS/NO in AD remain to be elucidated. A 
previous study demonstrated that A-induced ROS activated 
the ASK1-JNK pathway, which plays an important role in 
the pathogenesis of AD [40]. Another way A causes cell 
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death is through increasing Bim levels while also down reg-
ulating Bcl-2 levels, leading to the activation of Bax and 
neuronal cell death [41]. In addition, up-regulation of AKT 
restored the A-induced alterations of the Bcl-2 family 
members and suppressed the activation of JNK and caspa-
se-3 [42]. Based on these evidences, selective interference 
targeting to A generation and deposition could be utilized 
to treat or prevent AD.  
2.2  Tau hypothesis  
There are six tau isoforms existing in human brain, which 
are the products of alternative splicing from a single gene 
named MAPT (microtubule-associated protein tau) [43]. Tau 
proteins can stabilize tubulin and promote them assembly 
into microtubules [44]. Tau is a phosphoprotein that has 84 
putative phosphorylation sites that could be modified by 
serine/threonine protein kinases [3]. These phosphorylation 
kinases can be divided in two types: (1) Proline-directed 
protein kinases (PDPKs), such as GSK3 [45], cdk5 [46], 
and kinases belonging to MAPKs family; (2) Non-proline- 
directed protein kinase (NPDPK) such as protein kinase C 
(PKC), protein kinase A (PKA), partition defective1 (PAR1), 
and microtubule affinity regulating kinases (MARK) [47]. 
In neurodegeneration, tau is mainly modified by the proline- 
directed protein kinase, GSK3 [47]. Hyperphosphorylated 
tau accumulates in the somatodendritic compartment of neu-
rons, aggregates, and eventually forms NFTs [48]. It has 
been found that hyperphosphorylated tau causes mitochon-
drial dysfunction and induces oxidative stress [49]. Fur-
thermore, the pathological tau disturbs axonal transport in 
AD neurons causing synapse starvation and ultimately neu-
ronal damage [50]. In addition, recent studies have shown 
that phosphorylation of tau antagonizes apoptosis by stabi-
lizing -catenin [51,52]. The new findings reveal a dual role 
of tau phosphorylation in making the cells anti-apoptosis 
and leading to neurodegeneration. Although it is increas-
ingly clear that tau may act as a common mediator of neu-
rodegeneration for various upstream pathological events, a 
detailed map of causes and effects still remains elusive. 
2.3  Linking A and tau 
Based on the amyloid cascade hypothesis, A formation is 
the crucial step in the developing of AD. So, we ask where 
tau is to be placed in the amyloid cascade. Is tau a down-
stream target, or a paralleled effector of A toxicity? Evi-
dence from both in vivo and in vitro models suggests that 
there are three possible modes of interaction between these 
two pathologies: (1) A drives tau toxicity by causing hy-
perphosphorylation of tau; (2) A toxicity is critically de-
pendent on the presence of tau; (3) A and tau are synergis-
tic, thereby possibly amplifying each other’s toxic effects 
[3].  
3  Research interests of our laboratory 
3.1  Oxidative stress and neuronal cell death  
As discussed above, A-induced oxidative stress leads to 
neuron apoptosis. However, the mechanisms underlying the 
biological effects of oxidative stress remain largely un-
known. Mammalian Ste20-like kinases (MST) 1/2 and their 
Drosophila ortholog Hippo have been demonstrated that 
involved in diverse biological process ranging from organ 
size control, cell survival and death, to proliferation and 
tumorigenesis [53]. In our previous studies, we discovered 
that oxidative stress activates MST, activated MST1 phos-
phorylates Forkhead box O3 (FOXO3), and in turn, the ac-
tive form of FOXO3 promotes neuronal cell death through 
induction of the proapoptotic gene BIM [54]. Furthermore, 
we and others found that MST activity was regulated by 
Akt-induced phosphorylation [55,56], and c-Jun N-terminal 
kinase (JNK) worked together with MST1 through a feed-
back manner during cell death [57]. Until then, the mecha-
nisms that regulate MST1 in oxidative stress responses re-
mained unclear. Subsequently, we demonstrated that oxida-
tive stress induced the c-Abl-dependent tyrosine phosphor-
ylation of MST1 and increased the interaction between 
MST1 and FOXO3, thereby activating the MST1-FOXO3 
signalling pathway, leading to cell death in both primary 
culture neurons and rat hippocampal neurons [58]. Moreover, 
we recently discovered an evolutionarily conserved signal-
ling link between c-Abl and MST2 in regulating the neu-
ronal cell death that caused by Rotenone-induced oxidative 
stress [59].  
Based on our previous findings, the roles of c-Abl- 
MST1/2-FOXO3 cascade in oxidative stress induced neu-
ronal cell death have been revealed, and it will be important 
for us in future studies to determine the role of these path-
ways in the pathogenesis of AD by using gene manipulation 
in the rodent models. 
3.2  Retromer and APP processing 
The main function of Retromer, which has been well illus-
trated, is regulation of Wingless/Wnt secretion by recycling 
Wntless from early endosomes to the tans-Golgi network 
(TGN) [60,61]. Previous data indicate the Retromer to be 
functionally involved in the cellular trafficking of Me-
mapsin 2 (BACE) and SorLA, both of which have been 
demonstrated playing important roles in regulating APP 
processing [62,63]. In addition, deficits in Retromer transport 
are associated with sporadic AD and pronounced neuro-
degeneration in AD animal models [64]. In 2008, Muham-
mad et al. [65] demonstrated that Retromer deficiency could 
contribute to disease pathogenesis observed in late-onset 
Alzheimer’s disease using AD-mice and fly models. Anoth-
er line of evidence endorsing that Retromer activity is asso-
ciated with AD pathogenesis came from the clinical epide-
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miological studies. It has been reported that the mutations of 
SNX3 [61,66], which has been shown as an essential com-
ponent of Retromer in sorting wntless, is genetically associ-
ated with AD [67]. These data supported an association 
between Retromer deficiency and neurodegeneration, and 
suggested parallel increases in A generation. A recent 
study demonstrated that the majority of APP is processed in 
the TGN to produce A40, with a requirement for the Retro-
mer to sustain protein recycling from endosomes to the 
TGN [68]. However, the role of the Retromer in APP me-
tabolism is still largely unknown. Retromer control of APP 
processing may be through either direct (retrieving APP 
from endosomes) or indirect (retrieving SorLA from endo-
somes and consequently retaining APP in the secretory 
pathway). In either case, disruption of Retromer is predicted 
to cause accumulation of APP or APP derivatives in late 
endosomal compartments [69].  
Additionally, the cellular trafficking of BACE1 was also 
regulated by Retromer. Decreasing the expression of VPS26, 
a subunit of the Retromer complex, caused the accumula-
tion of BACE1 in early endosomes [62]. Furthermore, 
Down-regulating the expression of SNX6, another putative 
subunit of Retromer, increases the intracellular levels of 
BACE1, and following the enhancement of sAPP and C99 
levels [70]. Recently, the Retromer-associated sortilin has 
also been involved in the recycling of BACE1 from endo-
somes to TGN [71]. However, a wealth of study has sug-
gested that the retrograde transport of APP was distinct 
from that of BACE1 [72]. Other studies also argue that 
BACE1 and APP are mainly located in different lipid rafts 
which can be fused together during endocytosis [73], and 
this precise regulation restricts the encounter of APP and 
BACE1 [74]. These studies suggest that further investigat-
ing the regulation roles of APP and BACE1 trafficking may 
offer new therapeutic targets for AD treatment, which has 
been developing extensively in our laboratory.  
4  Conclusions and future directions 
In summary, the exact etiopathogenesis of Alzheimer’s dis-
ease is still obscure. The main neuropathology is the genesis 
and the defective clearance of the toxic fibrillar A. The 
proposed mechanisms include the amyloid cascade hypoth-
esis and the following tau hyperphosphorylation, vesicle 
trafficking disruption and oxidative stress. Current drugs 
target only the neurotransmitter dysfunction in AD, and 
although they can improve the symptoms, they do not have 
profound disease-modifying effects [21]. Strategies or agents 
which modify the disrupted trafficking of APP/BACE1 re-
duce aggregation of A, and therefore accelerate the clear-
ance of neurotoxic amyloid may provide better cognitive 
advantage in AD. 
Given that c-Abl-MST1/2 signalling transduction plays 
fundamental roles in oxidative stress induced neuronal cell 
death, the amount of upstream initiators or downstream 
sensors involved in this cascade still need further investi-
gating. Additionally, the Retromer complex has been demon-
strated as key regulator during AD development, although 
the mechanisms proposed by different researchers still re-
main controversial. Most of the current conclusions are 
generated by in vitro tissue cultural assays, and the biggest 
weakness of these assays is the difficulty in mimicking the 
real in vivo physiological/pathological processes. In this 
way, using the AD animal models (mutants or transgenic) to 
further investigate the underlying mechanisms should be a 
reasonable strategy. In addition, recent studies have shown 
that a missense mutation (D620N) of the VPS35 gene causes 
Parkinson’s disease (PD) [75,76]. According to the previous 
crystal structure research, this mutation localizes near the 
interface between VPS35 and VPS29 [77]. Therefore, we 
speculate that this mutation causes PD potentially by dis-
rupting the sorting efficiency of Retromer. Given that, it is 
also possible that this mutation exerts an effect on AD risk. 
Our laboratory is currently undergoing further investigation 
to test this hypothesis. 
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